- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 76
- States / cities
- Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Dothan, Alabama • Homestead, Florida • Tampa, Florida + 5 more
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more
- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chiefland, Florida + 19 more
- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Norwalk, California • Greenwood Village, Colorado + 17 more
- Conditions
- Uterine Leiomyoma, Uterine Fibroids
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix, Placebo for E2/NETA
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more
- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more